Mr. Khall Barrage appointed to Celtaxsys Board of Directors.

SAN FRANCISCO, CA – June, 2013 — Celtaxsys Inc., a privately-held biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders through innate immunity, today announced that Mr. Khalil Barrage has been appointed to the Board of Directors.

Celtaxsys Brings Leading Researchers in Respiratory Diseases Together to Serve on Medical Advisory Panel

SAN FRANCISCO, CA – January 23, 2013 — Celtaxsys, Inc., a privately-held biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders through innate immunity, today announced the appointments of Edward E. Philpot, M.D, J. Stuart Elborn, M.D., Richard B. Moss, M.D., Steven M. Rowe, M.D., M.S.P.H., and Michael S. Schechter, M.D., M.P.H., to its new Medical Advisory Panel.

Celtaxsys Initiates Phase 1 Study of CTX-4430 Oral Treatment for Pulmonary Inflammation

SAN FRANCISCO, CA – January 3, 2013 - Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H).

Brett Premack, PhD. Joins Celtaxsys as Chief Technology Officer

SAN FRANCISCO, October 23rd, 2012 -- Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat inflammatory disorders through innate immunity, today announced the appointment of life sciences technology expert, Brett A. Premack, Ph.D., as Chief Technology Officer.

Celtaxsys Acquires Clinical Stage Innate Immunity Drug for Inflammation

San Francisco, Calif., January 5, 2012 /PRNewswire / -- Celtaxsys, Inc. a privately held biotechnology company announced today that it has acquired CTX-4430 (formerly EP-501), a clinical stage drug candidate that inhibits the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H), from Estrellita Pharmaceuticals, Inc.

Dr. H. Daniel Perez Joins Celtaxsys Board of Directors

SAN FRANCISCO, June 6, 2011 /PRNewswire/ -- Celtaxsys, Inc., a private biopharmaceutical company defining new therapeutics in inflammation, announces the appointment of life sciences industry veteran, H. Daniel Perez, M.D., to its Board of Directors (BOD).

Michael Hanley, Ph.D. Chief Executive Officer

ATLANTA, Dec. 2, 2010 /PRNewswire/ -- Georgia -based drug discovery start-up, Celtaxsys, Inc. is pleased to announce that Dr. Michael Hanley has joined the company as its new Chief Executive Officer and Chairman of the Board of Directors